Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Search Results: Prevention, Detection & Risk (13 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

Men at High Genetic Risk for Prostate Cancer

Prevention:
Prostate

Men at High Genetic Risk for Prostate Cancer

The National Cancer Institute recently opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation.

GENetic Education Risk Assessment and TEsting Study (GENERATE)

Prevention:
Pancreatic

GENetic Education Risk Assessment and TEsting Study (GENERATE)

The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who carry a genetic mutation.

This study involves education about genetic testing, undergoing genetic testing for cancer risk and completion of a series of 4 sets of questionnaires.

For more information, visit the study website

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

 

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Prevention:
Pancreatic

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.

A Study in Hereditary Breast and Ovarian  Cancer Families to Provide Men With  Up-To-Date Information About the Personal  Importance of Genetic Testing (GEM)

Prevention:
Pancreatic
Prostate

A Study in Hereditary Breast and Ovarian Cancer Families to Provide Men With Up-To-Date Information About the Personal Importance of Genetic Testing (GEM)

The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative.

Women interested in the study should contact the project coordinator, Mary Kate Ladd, by phone at (877) 687-2720 (toll-free) or by email.

Making Genetic Testing Accessible (MAGENTA)

Prevention:
Breast
Ovarian

Making Genetic Testing Accessible (MAGENTA)

The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer.

Researchers also want to learn how these strategies may improve your understanding of genetics, your ability to complete a quiz about genetics, and your quality of life.

For more information, visit the study website

Pancreatic Cancer Early Detection Program

Prevention:
Pancreatic

Pancreatic Cancer Early Detection Program

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

BRCA Founder Outreach Study (BFOR)

Prevention:
Breast
Ovarian
Pancreatic
Prostate

BRCA Founder Outreach Study (BFOR)

BFOR is a research study looking at ways to make genetic testing easier. It offers BRCA testing at no cost to men and women age 25 or older, who have at least one Ashkenazi Jewish grandparent. The study is open to people who live in the Boston, New York, Los Angeles or Philadelphia metropolitan areas. For more information, visit the BFOR study website

The Women Choosing Surgical Prevention (WISP) Trial

Prevention:
Ovarian

Quality of Life:
High Risk But No Cancer

The Women Choosing Surgical Prevention (WISP) Trial

The goal of the WISP Study is to compare whether removal of fallopian tubes only, delaying removal of the ovaries can safely improve sexual functioning and menopausal symptoms compared to standard risk-reducing removal of the ovaries and fallopian tubes (also known as risk-reducing salpingo-oophorectomy or RRSO). You can visit the WISP website for more information.

 

PHACT Study: Population Health and Cancer Testing

Prevention:
Breast
Melanoma
Ovarian
Pancreatic
Prostate

PHACT Study: Population Health and Cancer Testing

The PHACT study offers genetic testing to women and men of Ashkenazi (Eastern European) Jewish ancestry, age 21 or older. This group is at least ten times more likely than the general population to inherit certain kinds of genetic mutations associated with cancer risk. The study is open to people who live in one of the nine Bay Area counties (Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano, Sonoma).  By participating in the UCSF Population Health and Cancer Testing (PHACT) study you will be provided with a saliva collection kit from Color Genomics, a genetic laboratory. Thirty genes will be analyzed, including BRCA1 and BRCA2, to identify mutations that increase the chance of cancer in both men and women of Ashkenazi (Eastern European) Jewish ancestry and genetic counseling support will be available with every test.  For more information, visit the UCSF Center for BRCA Research. 

Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer

Prevention:
Breast

Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better.

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

Prevention:
Breast

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

In this study, researchers want to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women.

Visit the study website for more information.

The WISDOM Study: Women Informed to Screen Depending on Measures of risk

Prevention:
Breast

The WISDOM Study: Women Informed to Screen Depending on Measures of risk

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website

Additional Results on Clinicaltrials.gov: Prevention, Detection & Risk + RAD51

2 Results

Clinical Trial Official Title
NCT04009148 Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
NCT02760849 Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

FORCE:Facing Our Risk of Cancer Empowered